Naveen Deenadayalu Selected Research

Atrial Fibrillation

6/2015	Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
6/2015	Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
8/2014	Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial.
8/2014	Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
3/2014	Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Naveen Deenadayalu Research Topics

Disease

5	Hemorrhage 06/2015 - 03/2014
5	Atrial Fibrillation 06/2015 - 03/2014
4	Stroke (Strokes) 06/2015 - 03/2014
2	Myocardial Infarction 08/2014 - 08/2014
2	Ischemic Stroke 08/2014 - 03/2014
1	Thromboembolism 06/2015
1	Embolism (Embolus) 08/2014
1	Transient Ischemic Attack 08/2014
1	Hemorrhagic Stroke 08/2014

Drug/Important Bio-Agent (IBA)

5	Warfarin (Coumadin)FDA LinkGeneric 06/2015 - 03/2014
4	AnticoagulantsIBA 06/2015 - 03/2014
4	edoxabanIBA 06/2015 - 08/2014
2	Vitamin K FDA Link 06/2015 - 08/2014
2	Factor Xa (Coagulation Factor Xa)IBA 08/2014 - 08/2014
1	Cytochrome P-450 CYP2C9IBA 06/2015
1	N(4)-oleylcytosine arabinosideIBA 08/2014
1	Factor Xa InhibitorsIBA 08/2014

Therapy/Procedure

1	Drug Tapering 06/2015